News Related to Interleukin-15 Receptor

Related coverage linked through entity extraction aliases.

ImmunityBio Reports 700% Revenue Growth, Expands Anktiva to 33 Countries and Lung Cancer

Feb 24, 2026

ImmunityBio announced $113 million in net product revenue for Anktiva in 2025, a 700% year-over-year increase, while expanding regulatory authorization to 33 countries and securing first approval for lung cancer treatment in Saudi Arabia.

Nektar Therapeutics Closes $460 Million Public Offering with Full Underwriter Exercise

Feb 14, 2026

Nektar Therapeutics completed a $460 million public offering on February 13, 2026, selling 7.6 million shares of common stock and pre-funded warrants. The clinical-stage biotechnology company is developing immunotherapy treatments for autoimmune diseases.